Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / Israel

Falling US Sales Continue To Cause Concern

November 2007 | Company Finance Alert

Israel's Teva Pharmaceutical Industries has joined a line of research-focused multinationals in posting disappointing Q307 results. While research-focused drugmakers have blamed falling profits on the rise of generics, Teva, as the world's largest manufacturer of generics, cannot hide behind the same

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *

Forgotten your password?

If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.

Free Trial To Pharmaceuticals & Healthcare Insight

TAKE A TRIAL >>
Related Insight Articles
Teva To Acquire Barr

Companies / Israel Not to be outdone by its research-focused rivals, Israel's Teva Pharmaceutical Industries has once again demonstrated its desire to expand by acquisition, launching a US$7.46bn bid for US-based generics...
July 2008
Momenta's Generic Version Of Copaxone To Be Reviewed

Companies / Israel The US FDA has accepted for review Momenta Pharmaceuticals' generic version of Teva Pharmaceutical's Copaxone (glatiramer).
July 2008
USTR's IP Concerns Lengthen

Industry / Israel In terms of volume, the Office of the US Trade Representative (USTR)'s 2008 Special 301 Report suggests that BMI's belief that this year will see the US push to improve intellectual property (IP) protection...
May 2008
Teva, Pfizer In Generics Pact

Companies / Israel Leading generic drug company Teva and US R&D-based major Pfizer have agreed to settle all outstanding litigation regarding three top-selling compounds. The deal refers to cancer drug Idamycin (idarubicin),...
November 2006
Teva Wins Pravachol Exclusivity, Beats Chinese Patent Filings

Companies / Israel Israel's Teva Pharmaceutical Industries is to receive 180-day US marketing exclusivity on its generic formulation of pravastatin sodium, better known as Bristol-Myers Squibb's blockbuster hyperlipidaemia...
April 2006
Middle East & Africa InsightMiddle East & Africa Channels Middle East & Africa Countries


All material on this site is protected by international copyright laws and use of this site is subject to our Terms & Conditions.
© 2008 Business Monitor International Ltd
Site powered by WORKSsitebuilder CMS